Login to Your Account

Clinic Roundup

Wednesday, May 30, 2012

• Medivir AB, of Stockholm, Sweden, said a Phase I trial has been initiated for MIV-711, a cathepsin K inhibitor to treat bone disorders such as osteoporosis, osteoarthritis and bone metastases. MIV-711 will be administered as single-ascending oral doses to healthy volunteers, followed by daily doses for seven days.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription